clarithromycin has been researched along with Bronchitis, Chronic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (94.44) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishinaga, H; Shah, SA; Takeuchi, K | 1 |
| Dubrovskaia, NV; Dvoretskiĭ, LI; Filimonova, OIu; Grudinina, SA; Iakovlev, SV; Sidorenko, SV | 1 |
| Weiss, LR | 1 |
| Freudenstein, J; Hauke, W; Henneicke-Von Zepelin, HH; Köhler, G | 1 |
| Vanjaka, A; Weiss, K | 1 |
| Busman, T; Dobryniewska, M; Nalepa, P; Notario, G | 1 |
| Akhter, N; Anwer, N; Fareed, A; Ghori, RA; Imran, K; Iqbal, ZH; Javaid, A; Khan, MH; Khan, MK; Khan, S; Khan, SU; Mahmood, K; Rahman, F; Siddqui, SJ; Ullah, S | 1 |
| Allegra, L; Huchon, G; Izquierdo, JL; Jones, P; Sagnier, PP; Schaberg, T; Wilson, R | 1 |
| Cots, JM; Llor, C; Miravitlles, M; Molina, J; Naberan, K | 2 |
| Amsden, GW; De Salvo, MC; Dunne, MW; Lainez-Ventosilla, A; Swanson, RN | 1 |
| Busman, T; Gotfried, M; Notario, G; Palmer, R; Spiller, J | 1 |
| Mikasa, K | 1 |
| Anzueto, A; Choudhri, S; Haverstock, D; Kureishi, A; Niederman, MS; Perroncel, R; Sethi, S | 1 |
| Bishai, WR | 1 |
| Avgeri, SG; Dimopoulos, G; Falagas, ME; Matthaiou, DK; Siempos, II | 1 |
| McCarty, JM; Pierce, PF | 1 |
3 review(s) available for clarithromycin and Bronchitis, Chronic
| Article | Year |
|---|---|
Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin.
Topics: Acute Disease; Anti-Bacterial Agents; Bronchitis, Chronic; Clarithromycin; Humans; Immunologic Factors; Maxillary Sinusitis; Treatment Outcome | 2006 |
Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Cefixime; Clarithromycin; Humans; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2008 |
10 trial(s) available for clarithromycin and Bronchitis, Chronic
| Article | Year |
|---|---|
Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2002 |
Esberitox N as supportive therapy when providing standard antibiotic treatment in subjects with a severe bacterial infection (acute exacerbation of chronic bronchitis). A multicentric, prospective, double-blind, placebo-controlled study.
Topics: Adjuvants, Immunologic; Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Humans; Lung Diseases, Obstructive; Pilot Projects; Plant Extracts; Roxithromycin; Time Factors | 2002 |
An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exa
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis, Chronic; Clarithromycin; Female; Humans; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2002 |
Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Bacterial Infections; Bronchitis, Chronic; Clarithromycin; Delayed-Action Preparations; Double-Blind Method; Drug Resistance, Bacterial; Humans; Middle Aged; Patient Compliance; Treatment Outcome | 2003 |
Cefaclor AF vs Clarithromycin in acute exacerbation of chronic bronchitis (B3M-PK-AJBG).
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis, Chronic; Cefaclor; Clarithromycin; Female; Humans; Male; Middle Aged; Single-Blind Method; Treatment Outcome | 2003 |
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines | 2004 |
Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Moraxella catarrhalis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis, Chronic; Clarithromycin; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Treatment Outcome | 2005 |
Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Drug Therapy, Combination; Epidemiologic Methods; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Oxygen Inhalation Therapy; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2005 |
Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis, Chronic; Cefprozil; Cephalosporins; Clarithromycin; Demography; Double-Blind Method; Drug Administration Schedule; Humans; Microbial Sensitivity Tests; Middle Aged; Recurrence; Treatment Outcome | 2001 |
5 other study(ies) available for clarithromycin and Bronchitis, Chronic
| Article | Year |
|---|---|
Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway.
Topics: Anti-Bacterial Agents; Bronchi; Bronchitis, Chronic; Cell Line; Chronic Disease; Clarithromycin; Dual Specificity Phosphatase 1; Epithelial Cells; Gene Expression Regulation; Humans; Mucin 5AC; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Sinusitis; Tumor Necrosis Factor-alpha | 2017 |
[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithromycin; Female; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Treatment Outcome; Young Adult | 2007 |
[Acute exacerbated chronic bronchitis. Antibiotics in comparison].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Smoking; Time Factors | 2003 |
Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Clavulanic Acid; Cost of Illness; Cost-Benefit Analysis; Data Collection; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2004 |
[New treatment not based on MIC for infectious diseases--making use of experience of macrolide long-term therapy].
Topics: Adult; Aged; Aged, 80 and over; Animals; Bronchiectasis; Bronchitis, Chronic; Clarithromycin; Erythromycin; Female; Humans; Lung Neoplasms; Macrolides; Male; Mice; Middle Aged | 2005 |